O6-Benzylguanine enhances the in vitro immunotoxic activity of temozolomide on natural or antigen-dependent immunity

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 3, 1999, Pages 1292-1300

  Alvino, Ester ^a   Pepponi, Rita ^b   Pagani, Elena ^b   Lacal, Pedro Miguel ^b   Nunziata, Corrado ^b   Bonmassar, Enzo ^b   D'Atri, Stefania ^b  

^a CNR   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; ANTIGEN; INTERLEUKIN 2; TEMOZOLOMIDE;

ARTICLE; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; METHYLATION; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE; DACARBAZINE; ENZYME INHIBITORS; GUANINE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; MONOCYTES; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED;

EID: 0032732618     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumor cells. Br J Cancer 87:1299-1302.
2. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJ, Brampton M and Stevens MF (1995) Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910-913.
3. Bonmassar E, D'Atri S, Turriziani M and Giuliani A (1994) In vitro combined effects of triazene compound and interferon-beta on natural immunity against lymphoblastoid cells. Studies at effector and target cell level. Immunopharm Immunot 16:695-715.
4. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, Colquhoun I, Lewis P and Brampton MH (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484-488.
5. Bradford MM (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72:248-254.
6. Carethers JM, Hawn MT, Chauhan DP, Luce MC, Marra G, Koi M and Boland CR (1996) Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine. J Clin Invest 98:199-206.
7. 6-Methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung and ovary. Cancer Res 51:4131-4134.
8. Cohen GL and Falkson CI (1998) Current treatment options for malignant melanoma. Drugs 58:791-799.
9. 6-alkylguanine DNA alkyltransferase levels: Studies with blasts of leukaemic patients. Ann Oncol 6:389-393.
10. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E and Jiricny J (1998) Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54:334-341.
11. 6-alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 15:279-292.
12. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 51:3367-3372.
13. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 87:5368-5372.
14. 6-Benzylguanine and its role in chemotherapy. Clin Cancer Res 3:837-847.
15. - human tumor cells. Cancer Res 50:7908-7911.
16. 6-alkylgunine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis 7:745-749.
17. Giampietri A and Bonmassar E (1978) Drug-induced modulation of immune responses in mice, effect of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) and cyclophosphamide (Cy). J Immunopharmacol 1:61-65.
18. Jiricny J (1996) Mismatch repair and cancer, in Genetic Instability in Cancer (Lindahl T ed) pp 47-68, Cancer Surveys, Cold Spring Harbor University Press, Cold Spring Harbor, NY.
19. Karran P and Bignami M (1992) Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res 20:2933-2940.
20. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM and Modrich P (1993) An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 90:6424-6428.
21. 6-alkylguanine-DNA-alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 88:452-456.
22. Liu L, Markowitz S and Gerson SL (1996) Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 56:5375-5379.
23. Miyoshi I, Kubonishi J and Yoshimoto S (1981) Type-C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukemic T-cells. Nature (Lond) 294:770-771.
24. Modrich P (1997) Strand-specific mismatch repair in mammalian cells. J Biol Chem 272:24727-24730.
25. 6-alkylguanine alkyltransferase activity in Chinese hamster V79 cells following selection with chloroethylating agents. Carcinogenesis 9:45-49.
26. 6-methylguanine-DNA methyltransferase and uracil-DNA glycosylase in human organs. Carcinogenesis 4:1565-1568.
27. Nardelli B, Puccetti P, Romani L, Sava G, Bonmassar E and Fioretti MC (1984) Chemical xenogenization of murine lymphoma cells with triazene derivatives: Immunotoxicological studies. Cancer Immunol Immunother 17:213-217.
28. Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hoffman R, Stevens MFG, Brampton MH and Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287-291.
29. Ockert D, Schmitz M, Hampl M and Rieber EP (1999) Advances in cancer immunotherapy. Immunol Today 20:63-65.
30. 6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50:6119-6129.
31. 6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB10-277, a new DTIC analogue. Cancer Chemother Pharm 31:240-246.
32. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW and Slack JA (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo 5,1-d-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831) a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846-5852.
33. 6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia (Baltimore) 9:1888-1895.
34. 6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 52:249-258.
35. 6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. Biochem Pharmacol 38:457-462.
36. 6-benzylguanine/temozolomide combination: An evaluation in a human xenograft model. Cancer Chemother Pharmacol 40:266-272.
37. 6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer 73:1049-1952.
38. 6-benzylguanine: A comparative study in vitro. Br J Cancer 73:482-490.
39. Woll PJ, Crowther D, Johnson PWM, Soukop M, Harper PG, Harris M, Brampton MH and Newlands ES (1995) Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br J Cancer 72:183-184.